MARKET

AQST

AQST

Aquestive Therapeutics
NASDAQ
4.180
+0.050
+1.21%
Pre Market: 4.060 -0.12 -2.87% 08:44 04/09 EDT
OPEN
4.240
PREV CLOSE
4.130
HIGH
4.280
LOW
4.145
VOLUME
103
TURNOVER
0
52 WEEK HIGH
7.55
52 WEEK LOW
2.120
MARKET CAP
510.15M
P/E (TTM)
-5.3344
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AQST last week (0330-0403)?
Weekly Report · 3d ago
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 
TipRanks · 03/31 19:34
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM)
TipRanks · 03/30 19:30
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting
TipRanks · 03/30 13:10
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST)
TipRanks · 03/30 12:51
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
TipRanks · 03/30 11:16
Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis
Benzinga · 03/30 11:15
Aquestive plans PK, human factors studies ahead of Anaphylm NDA resubmission in Q3 2026
Reuters · 03/30 11:05
More
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Webull offers Aquestive Therapeutics Inc stock information, including NASDAQ: AQST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AQST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AQST stock methods without spending real money on the virtual paper trading platform.